Scarica l'app Stockscreener
33.85
2.08%
-0.72
Precedente Chiudi:
$34.57
Aprire:
$34.46
Volume 24 ore:
594.17K
Relative Volume:
0.57
Capitalizzazione di mercato:
$2.97B
Reddito:
$23.38M
Utile/perdita netta:
$-155.22M
Rapporto P/E:
-15.46
EPS:
-2.19
Flusso di cassa netto:
$-134.36M
1 W Prestazione:
-3.84%
1M Prestazione:
+0.47%
6M Prestazione:
+54.43%
1 anno Prestazione:
+34.54%
Intervallo 1D:
$33.31
$34.63
Intervallo di 1 settimana:
$33.31
$35.27
Portata 52W:
$13.45
$37.08
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Nome
Ideaya Biosciences Inc
Settore
Industria
Telefono
650-443-6209
Indirizzo
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Confronta IDYA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
33.85 | 3.03B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-09-18 | Iniziato | Guggenheim | Buy |
| 2025-09-04 | Iniziato | Barclays | Overweight |
| 2025-09-04 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-07-22 | Iniziato | TD Cowen | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-26 | Iniziato | Wells Fargo | Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-11-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2024-03-08 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Outperform |
| 2023-05-24 | Iniziato | Goldman | Buy |
| 2023-04-24 | Aggiornamento | Stifel | Hold → Buy |
| 2023-03-23 | Iniziato | Berenberg | Buy |
| 2023-02-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-28 | Iniziato | CapitalOne | Overweight |
| 2022-10-27 | Iniziato | Citigroup | Buy |
| 2022-08-15 | Downgrade | Stifel | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-10 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-11 | Iniziato | Guggenheim | Buy |
| 2020-10-07 | Iniziato | Wedbush | Outperform |
| 2020-09-01 | Iniziato | Northland Capital | Outperform |
| 2020-07-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-06 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-13 | Iniziato | ROTH Capital | Buy |
| 2019-10-17 | Iniziato | Oppenheimer | Outperform |
| 2019-09-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-17 | Iniziato | Citigroup | Buy |
| 2019-06-17 | Iniziato | JP Morgan | Neutral |
| 2019-06-17 | Iniziato | Jefferies | Buy |
Mostra tutto
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
IDEAYA Biosciences (NASDAQ:IDYA) Nasdaq 100 Index Research-Driven Model - Kalkine Media
Avoiding Lag: Real-Time Signals in (IDYA) Movement - Stock Traders Daily
IDEAYA Biosciences Sees Unusually Large Options Volume (NASDAQ:IDYA) - MarketBeat
Will IDEAYA Biosciences Inc. stock benefit from commodity pricesCandlestick Trading Patterns & Next-Level Stock Intelligence, Now Free - bollywoodhelpline.com
IDEAYA Biosciences Earnings Notes - Trefis
Squarepoint Ops LLC Sells 51,937 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Biotech Stocks Shine After Hours: Novo Nordisk, IDEAYA, Healthcare Triangle Among Gainers - Nasdaq
Will IDEAYA Biosciences Inc. stock rally after Fed decisions2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - Улправда
Technical Reactions to IDYA Trends in Macro Strategies - Stock Traders Daily
How IDEAYA Biosciences Inc. (30J) stock compares with tech leaders2025 Technical Patterns & Community Supported Trade Ideas - Улправда
Why IDEAYA Biosciences Inc. stock attracts high net worth investorsJuly 2025 Price Swings & Weekly High Return Stock Opportunities - Улправда
Aug EndMonth: Why IDEAYA Biosciences Inc. stock attracts high net worth investorsStock Surge & Accurate Trade Setup Notifications - Улправда
Why IDEAYA Biosciences Inc. stock appeals to dividend seekersQuarterly Profit Summary & Precise Swing Trade Alerts - Улправда
How interest rate cuts could boost IDEAYA Biosciences Inc. stockChart Signals & Consistent Return Investment Signals - Улправда
Gap Down: Will IDEAYA Biosciences Inc. stock outperform growth indexesJuly 2025 Update & Expert-Curated Trade Recommendations - Улправда
How buybacks impact IDEAYA Biosciences Inc. stock valueJuly 2025 Sentiment & Daily Profit Maximizing Tips - DonanımHaber
Why IDEAYA Biosciences Inc. (30J) stock remains top ratedPortfolio Return Summary & AI Powered Buy and Sell Recommendations - DonanımHaber
How supply shortages influence IDEAYA Biosciences Inc. (30J) stockJuly 2025 Pullbacks & Low Risk Investment Opportunities - Улправда
Aug Weekly: Why IDEAYA Biosciences Inc. stock attracts high net worth investorsTrade Signal Summary & Weekly Momentum Picks - Улправда
Will IDEAYA Biosciences Inc. stock outperform growth indexesMarket Rally & Accurate Entry/Exit Alerts - Улправда
Antibody Optimization Service Market Set to Reach USD 6.07 Billion by 2034, Growing at an 8.45% CAGR Amid Advances in Gene-Editing Technologies - GlobeNewswire Inc.
IDEAYA Biosciences (IDYA): Valuation Check After Key Darovasertib Trial Milestone and Pipeline Progress - simplywall.st
Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial - Yahoo Finance
Ideaya Biosciences to regain rights for two programs as GSK ends partnership - Investing.com Australia
Ideaya Biosciences to regain rights for two programs as GSK ends partnership By Investing.com - Investing.com South Africa
IDEAYA Biosciences (NASDAQ: IDYA) outlines GSK exit, program transfer and cash runway - Stock Titan
Redmile Group LLC Sells 102,106 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA financials not impacted by GSK termination, says Mizuho - MSN
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma - BioSpace
IDEAYA Hits Full Enrolment In Pivotal Trial Of Darovasertib For Metastatic Uveal Melanoma - RTTNews
IDEAYA Biosciences Completes Targeted Full Enrollment in Trial of Darovasertib With Pfizer's Crizotinib - marketscreener.com
IDEAYA completes enrollment for pivotal cancer drug trial - Investing.com
IDEAYA completes enrollment for pivotal cancer drug trial By Investing.com - Investing.com South Africa
IDEAYA Biosciences (NASDAQ: IDYA) wraps mUM 2/3 enrollment, PFS in 1Q 2026 - Stock Titan
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers - BioSpace
Stempoint Capital LP Purchases 98,886 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences submits IND for novel cancer drug IDE574 By Investing.com - Investing.com Australia
IDEAYA Biosciences submits IND for novel cancer drug IDE574 - Investing.com India
Ideaya Biosciences announces IND submission for IDE574 - marketscreener.com
Ideaya Biosciences Announces Ind Submission For Ide574 - TradingView — Track All Markets
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers – Company Announcement - Financial Times
Hsbc Holdings PLC Has $804,000 Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
JPMorgan Chase & Co. Purchases 115,827 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Trading the Move, Not the Narrative: (IDYA) Edition - news.stocktradersdaily.com
Ideaya disclosed termination of GSK license agreement - MSN
GSK (GSK) Plans to End Agreement with Ideaya Biosciences - GuruFocus
GSK cuts the cord on Ideaya collaboration, letting go of 2 programs - Fierce Biotech
IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 52-Week HighHere's Why - MarketBeat
Federated Hermes Inc. Has $97.27 Million Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
GSK ends collaboration with IDEAYA for two candidates - MSN
Ideaya Biosciences Inc Azioni (IDYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):